MAKING THE PRESS
Tempus most recently established a collaboration with Mary Crowley Cancer Research with the objective of expanding research options for lung cancer patents. As part of the collaboration, Tempus will be a preferred provider for Mary Crowley Cancer Research to perform molecular sequencing, analysis and provide clinical support for patients diagnosed with lung cancer.
The Board of Mary Crowley Cancer Research is delighted to announce the appointment of Ashley E. Ross, M.D., PhD, as Executive Medical Director. Dr. Ross brings a strong research background and outstanding leadership skills to direct Mary Crowley’s patient care and research initiatives.
The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
Mary Crowley Cancer Research has opened a new Phase I clinical trial for advanced Type 1 Ewing sarcoma, a rare bone cancer affecting children, adolescents, and young adults. The first patient has received the investigational therapy and is currently undergoing a response evaluation. Patients with rapidly recurrent Ewing sarcoma have less than a 10% chance of surviving more than five years, and yet no new treatments have been developed in decades. Read Full Story Here.
Pushing Hope Marine Industry Charity Events raised over $180k for Mary Crowley Cancer Research through a series of charity events August 18-20 in the greater St. Louis area. Read Full Story Here.
